Shares of NextCure, Inc. (NASDAQ:NXTC – Get Rating) have been given an average recommendation of “Buy” by the six analysts that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $17.00.
Several research analysts recently issued reports on NXTC shares. Zacks Investment Research lowered shares of NextCure from a “buy” rating to a “hold” rating in a research report on Wednesday, March 9th. LADENBURG THALM/SH SH began coverage on shares of NextCure in a research note on Tuesday, March 1st. They issued a “buy” rating and a $16.00 price target for the company.
NASDAQ:NXTC traded down $0.11 during midday trading on Monday, hitting $4.16. The company had a trading volume of 92,302 shares, compared to its average volume of 113,563. NextCure has a 52-week low of $4.14 and a 52-week high of $9.29. The stock’s fifty day moving average price is $4.92 and its 200-day moving average price is $5.78. The company has a market capitalization of $115.32 million, a PE ratio of -1.66 and a beta of 0.01.
Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its stake in shares of NextCure by 257.4% in the fourth quarter. JPMorgan Chase & Co. now owns 8,774 shares of the company’s stock worth $53,000 after purchasing an additional 6,319 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in NextCure during the fourth quarter valued at $60,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in NextCure during the third quarter valued at $99,000. Marquette Asset Management LLC increased its position in NextCure by 36.2% during the fourth quarter. Marquette Asset Management LLC now owns 17,500 shares of the company’s stock valued at $105,000 after acquiring an additional 4,652 shares during the last quarter. Finally, Cubist Systematic Strategies LLC increased its position in NextCure by 27.8% during the fourth quarter. Cubist Systematic Strategies LLC now owns 18,383 shares of the company’s stock valued at $110,000 after acquiring an additional 4,001 shares during the last quarter. 52.38% of the stock is owned by institutional investors.
About NextCure (Get Rating)
NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors.
- Get a free copy of the StockNews.com research report on NextCure (NXTC)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.